Licensing agreement
The independent Dutch research organisation TNO, of Delft, agreed a licence and collaboration deal with Clinquest Group of Amsterdam for clinical development and commercialisation of CQ-07001 in anti-inflammatory and tissue regeneration applications. TNO will receive milestone fees and royalty payments, but financial details were not disclosed.
CQ-07001 is a human protein that has shown to be a powerful agonist to Toll-like receptor 3 (TLR 3), which is implicated in recognising pathogens and inducing immune responses. Studies performed by TNO have shown that TLR 3 is stimulated by CQ-07001 and subsequently triggers anti-inflammatory and tissue repair responses.
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 